September 21, 2024Journal of Clinical MedicineOpen Access

Omalizumab for the Treatment of Chronic Spontaneous Urticaria in Adults and Adolescents: An Eight-Year Real-Life Experience

View Full Paper

Ask AI

Bookmark

Authors

PCPaolo CalzariUniversity of Milan AGAlessandra Chiei GalloUniversity of Milan FBFrancesca BareiFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Discussion

Member takes

Implication

Retrospective study demonstrates high long-term drug survival in severe chronic spontaneous urticaria, highlighting favorable clinical remission with omalizumab.

Key Points

Clinical remission drove high eight-year drug survival during omalizumab therapy for chronic spontaneous urticaria, with only 5.1% discontinuing due to ineffectiveness.
Overall drug survival reached 53.5% across the cohort, with early response occurring in 40.4% of individuals who presented with higher baseline total ige levels.
Retrospective study of 296 patients evaluated disease activity, total ige, and anti-thyroid autoantibodies to determine omalizumab treatment retention over time.
Supports the long-term safety of anti-ige monoclonal antibody therapy, while identifying comorbid autoimmune thyroiditis as a risk factor for treatment inefficacy.

Cite This Study

Calzari et al. (2024) studied this question.

synapsesocial.com/papers/68e57c15b6db64358751aee8 https://doi.org/10.3390/jcm13185610

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study demonstrates high long-term drug survival in severe chronic spontaneous urticaria, highlighting favorable clinical remission with omalizumab.

Omalizumab for the Treatment of Chronic Spontaneous Urticaria in Adults and Adolescents: An Eight-Year Real-Life Experience

Discussion

Member takes

Implication

Key Points

Cite This Study

Omalizumab for the Treatment of Chronic Spontaneous Urticaria in Adults and Adolescents: An Eight-Year Real-Life Experience

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider